Otolaryngology

Otolaryngology
Audio Summaries

The literature in otolaryngology doesn't slow down, and the papers you skip might be the ones that change your practice. OSLR turns the journals you'd read if you had the time into 3-minute audio summaries. Listen on your commute, between cases, whenever.

10 active journals741 audio summaries

Recent summaries

The latest articles summarized from otolaryngology journals.

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome

The New England journal of medicine|Sep 23, 2026

This study investigates the efficacy and safety of etuvetidigene autotemcel (etu-cel), an autologous gene therapy, for treating Wiskott-Aldrich syndrome, a rare genetic disorder. The results indicate a high overall survival rate of 96% at both 1 and 5 years post-treatment, along with a significant reduction in severe infections and bleeding events after therapy. The findings suggest that etu-cel provides a sustained clinical benefit for patients with this condition.

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

The New England journal of medicine|Sep 23, 2026

This phase 1 study investigates the safety and efficacy of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. The results indicate a high response rate (100%) with a significant proportion achieving complete response (79%), while adverse events, particularly cytokine release syndrome and neurotoxicity, were mostly mild. The findings suggest that anito-cel may be a promising treatment option for this challenging patient population.

Clinical Uses of Common Genetic Variants Associated with Common Diseases

The New England journal of medicine|Sep 23, 2026

The authors investigate why the integration of polygenic risk scores and genomic knowledge into clinical practice for common adult-onset diseases has been slow, despite advancements in genomics and the identification of numerous genetic variants associated with these conditions. They explore potential applications of these scores and pharmacogenomics in improving prevention and treatment strategies as genome sequencing becomes more accessible.

Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial

JAMA|Sep 23, 2026

The study aimed to determine whether intravenous tenecteplase administered before endovascular thrombectomy (EVT) improves outcomes in patients with moderate to severe basilar artery occlusion presenting 4.5 to 24 hours after stroke onset. The findings revealed no significant difference in functional independence or safety outcomes between the tenecteplase plus EVT group and the EVT alone group, suggesting that the addition of tenecteplase does not enhance recovery in this patient population.

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

The New England journal of medicine|Sep 23, 2026

The authors aimed to determine whether screening with a multicancer early-detection test, in addition to usual care, reduces the incidence of late-stage cancers (stage III or IV) compared to usual care alone. In a randomized controlled trial involving over 142,000 participants, they found no significant difference in the incidence rates of stage III or IV cancers between the two groups after three screening rounds. While there was a trend towards a lower incidence of stage IV cancers, the results were not conclusive, indicating the need for further follow-up.

Understanding peripheral arterial disease in the current era

Lancet (London, England)|Sep 22, 2026

The authors aim to address the underacknowledgment, underdiagnosis, and undertreatment of peripheral arterial disease (PAD) in the context of atherosclerotic cardiovascular disease, highlighting its increasing prevalence and significant mortality rates. They emphasize the need for improved recognition and interdisciplinary measures to enhance patient outcomes and advocate for better integration of preventive care and treatment strategies. This clinical series seeks to inform clinicians and policymakers about the global burden of PAD and effective approaches to manage it.

Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead

Lancet (London, England)|Sep 22, 2026

This paper aims to address the adverse impacts of peripheral arterial disease (PAD) and the disparities in outcomes among affected populations. The authors highlight the significant individual and societal burdens of PAD, particularly on underserved groups, and propose both short-term and long-term strategies to improve management and access to care, including enhanced awareness and multidisciplinary treatment approaches. The study emphasizes the need for targeted interventions to reduce the prevalence and consequences of PAD, especially in vulnerable communities.

Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment

Lancet (London, England)|Sep 22, 2026

The authors review current advancements in the management of peripheral arterial disease (PAD), particularly focusing on the effectiveness of medical therapy, supervised exercise, and the judicious use of revascularization procedures. They aim to address how to optimize treatment strategies to reduce cardiovascular risks, improve quality of life, and minimize limb loss in patients with varying severity of PAD. The paper highlights the complexities of PAD management due to its multifaceted nature and the potential overuse of invasive interventions.

Vaccines for Cancer: A Translational Science Review

JAMA|Sep 21, 2026

This review examines the advancements in cancer vaccine development, driven by improved understanding of tumor immunology and vaccine technology, and aims to assess the potential of these vaccines in treating various cancers. The authors highlight the mechanisms of action, types of antigens used, and the integration of cancer vaccines with other therapies, while also noting the generally mild adverse effects associated with these vaccines. Ultimately, the review emphasizes the ongoing clinical trials exploring the role of cancer vaccines in both treatment and primary prevention of cancer.

Developing roadmaps for advancing practice, research, and policy in the arts and health

Lancet (London, England)|Sep 21, 2026

The authors aim to develop actionable roadmaps for integrating the arts into health and wellbeing systems globally, addressing the emerging evidence of arts engagement's health benefits. They propose key strategies, including ensuring universal access to arts opportunities, implementing population-level approaches to tackle health inequities, and fostering clinical innovation in arts therapies. Additionally, they highlight the importance of cross-sector collaboration and investment to support these initiatives.

Start listening to otolaryngology research

14-day free trial. Pick your journals and go.